This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
Daraxonrasib combined with chemotherapy caused substantial tumor shrinkage in patients with pancreatic cancer that had spread to other parts of the body, according to new results from a Phase I/II clinical trial.
In a presentation of the results from the RMC-GI-102 trial at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, the principal investigator said the drug combination not only shrank tumors but also showed encouraging prolonged disease control when used in patients who had not previously received treatment for metastatic disease.
Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center, New York City, U.S., said, "Pancreatic cancer remains one of the most challenging cancers to treat, particularly because more than half of patients present with disease that has already spread to other organs. We need effective treatments that can achieve deep responses and prolong disease control to curb this aggressively devastating disease.
"For most patients with previously untreated metastatic pancreatic cancer, chemotherapy remains the foundation of treatment. Although chemotherapy can shrink tumors by a modest amount and help some patients, the cancer frequently develops resistance and begins growing again."
Most patients with metastatic pancreatic cancer treated with standard chemotherapy survive for between eight and 11 months, and only 3% are alive five years after diagnosis. Tumor shrinkage is seen in only 23%–42% of patients treated with chemotherapy, and most tumors start to grow again after five to six months.
Source link







